



**KINEXUS**

## **Kinexus Bioinformatics Corporation Announces the Appointment of Two New Directors to its Board**

*Senior Executives Bring Diverse Expertise to the Board of Kinexus*

**FOR IMMEDIATE RELEASE AUGUST 10, 2004**

VANCOUVER, British Columbia - Kinexus Bioinformatics Corporation, is pleased to announce the appointments of Mr. Justin Stephenson and Mr. Joel Bellenson to the Board of Directors of Kinexus. "We are delighted to welcome these two high-caliber executives to our Board," said Dr. Steven Pelech, Founder, President and Chief Scientific officer of Kinexus. "Both individuals bring over twenty years of experience in the healthcare and high technology industries and in-depth knowledge of these sectors. Their expertise in finance, corporate and business development will greatly facilitate realization of our corporate objectives as Kinexus embarks on its next growth phase".

Mr. Justin Stephenson has been actively involved in the Canadian life sciences and health care industry for over a decade. He is currently the Founder and President of Galiano Ventures Inc., a Vancouver based venture capital, private equity and management services firm specializing in the life sciences industries. Prior to founding Galiano Ventures in 2004, he was the Managing Partner of the Life Sciences Fund for RBC Capital Partners where he administered funds in excess of C\$150 million in more than 30 investments in private and public biotech and healthcare companies in Canada and the United States. Prior to RBCP, he was Vice-President of Business Development for Elemental Research Inc., a bio-analytical contract research organization serving both biotech and pharmaceutical companies world wide, and has worked for the BC Trade Development Corporation, Chemical Industries Associations, PriceWaterhouseCoopers and Alcan International Ltd in the U.K.

Mr. Joel Bellenson has been the founder and Chief Executive Officer of several high tech companies within North America. He is currently the President and CEO of Upstream Biosciences Inc, a Vancouver-based company offering sophisticated applications to perform advanced modeling of cell systems, protein signalling and gene regulatory pathways. He is also a partner with Libra Digital, a consulting practice that incubates new technologies in the fields of biotechnology and alternative energy. Prior to BioCAD he was the co-Founder and CEO of DigiScents and the Co-Founder, CEO, Chief Strategist and Director of DoubleTwist (originally Pangea Systems) in Oakland, California, which was one of the 5 largest bioinformatics operations in the world. His companies raised over US\$100 million in investment from leading venture capitalists. He was also founder and manager of the DNA Core Facility Services at Stanford University.

Kinexus Bioinformatics Corporation is a private, biopharmaceutical company engaged in the development of innovative methods to establish the relationships of signalling proteins within cellular communication networks. The application of this knowledge strategically positions Kinexus and its clients to advance drug development, rational drug design, disease diagnosis and personalized therapies to improve human health.

**For further information, please contact Kinexus Bioinformatics Corporation toll free at 1-866-KINEXUS or visit our website at [www.kinexus.ca](http://www.kinexus.ca).**

**PRESS RELEASE - 2004 AUGUST 10**